Company intelligence / Profile preview

Adivio

Puchheim, Bavaria, Germany

Ownership: Private
Employees: ~25
Development stage: Other

Overview

adivo has built species-specific phage display monoclonal antibody libraries for dogs and cats and has advanced a proprietary oncology antibody into a first-in-patient canine solid tumor study started in early 2023, with additional pre-clinical programs in oncology and inflammatory diseases.[1][3][7][9]

Therapeutic areas: OncologyImmunologyOther
Modalities: Monoclonal antibodyBiologic
Industry: Veterinary

Partnerships

Zoetis (research collaboration since 2021; acquirer in 2023)[3][7][9]Bayer Animal Health (global collaboration agreement announced in 2019)[1]Undisclosed leading animal health company (global collaboration agreement announced 2021, likely Zoetis prior to acquisition)[1]FyoniBio (manufacturing partnership to strengthen manufacturing setup ahead of first-in-animal studies)[1]

Beyond the preview

Go deeper on Adivio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adivio.

Explore the full profile